tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Nuvalent’s Promising Prospects: Buy Rating Backed by Pivotal Drug Readout and Strong Pipeline Potential
PremiumRatingsNuvalent’s Promising Prospects: Buy Rating Backed by Pivotal Drug Readout and Strong Pipeline Potential
19d ago
Nuvalent Completes New Drug Application Submission
Premium
Company Announcements
Nuvalent Completes New Drug Application Submission
1M ago
Nuvalent presents data from ARROS-1 trial of zidesamtinib
Premium
The Fly
Nuvalent presents data from ARROS-1 trial of zidesamtinib
2M ago
Nuvalent initiated with an Overweight at Piper Sandler
PremiumThe FlyNuvalent initiated with an Overweight at Piper Sandler
2M ago
Nuvalent Reports Q2 2025 Financials and Pipeline Progress
Premium
Company Announcements
Nuvalent Reports Q2 2025 Financials and Pipeline Progress
3M ago
Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
Premium
Ratings
Nuvalent’s Promising Drug Pipeline and Strategic Trials Drive Buy Rating
3M ago
Nuvalent doses first patient in Alkazar trial
PremiumThe FlyNuvalent doses first patient in Alkazar trial
3M ago
Nuvalent’s Promising Biotech Advancements: Buy Rating Backed by Strong Clinical Results
Premium
Ratings
Nuvalent’s Promising Biotech Advancements: Buy Rating Backed by Strong Clinical Results
4M ago
Nuvalent assigned Buy rating, $105 price target at Goldman Sachs
Premium
The Fly
Nuvalent assigned Buy rating, $105 price target at Goldman Sachs
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100